Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC26A3 | P40879 | 5/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848465 | 0.97 | MAOB (0.38) | MAOBMTNR1AMTNR1BHTR2BSLC26A3 | |
| SCHEMBL1858690 | 0.87 | GPR52 (0.48) | MTNR1AMTNR1BGPR52 | |
| SCHEMBL1849327 | 0.84 | MTNR1A (0.46) | MAOBMTNR1AMTNR1BHTR2BALOX5 | |
| SCHEMBL1848567 | 0.79 | ALOX5 (0.56) | MAOBMTNR1AMTNR1BHTR2BSLC26A3 | |
| Bromide SCHEMBL1852155 | 0.78 | ALOX5 (0.54) | MAOBMTNR1AMTNR1BHTR2BSLC26A3 | |
| SCHEMBL1858526 | 0.77 | MAPT (0.39) | HTR2BABHD6IDO1 | |
| SCHEMBL1852157 | 0.76 | ALOX5 (0.52) | MAOBMTNR1AMTNR1BHTR2BSLC26A3 | |
| SCHEMBL1854575 | 0.73 | HTR2B (0.42) | HTR2B | |
| SCHEMBL1852178 | 0.72 | GPR52 (0.56) | MTNR1AMTNR1BGPR52 | |
| SCHEMBL27611980 | 0.71 | EDNRA (0.64) | EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | MAOB 1106/4885MTNR1A 108/4885MTNR1B 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.